» Articles » PMID: 24756830

Patterns of Surveillance Following Curative Intent Therapy for Gastroesophageal Cancer

Overview
Publisher Springer
Date 2014 Apr 24
PMID 24756830
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Our aims were to examine surveillance strategies after curative treatment of early gastroesophageal (GE) cancer and to evaluate the impact of different approaches on outcomes.

Methods: A total of 292 patients with non-metastatic GE cancer who were referred to the BC Cancer Agency from 2001 to 2010 for curative intent treatment were analyzed. Surveillance practices were classified into the following: cohort 1 (discharge to general practitioner), cohort 2 (follow-up by oncologist with clinical assessments), cohort 3 (specialist follow-up with laboratory investigations), and cohort 4 (specialist follow-up with imaging or endoscopy). Outcomes were compared across cohorts using Kaplan-Meier methods and Cox regression.

Results: In total, median age was 63 years and 76 % were men. Eighty-nine (30%), 18 (6%), 32 (11%), and 152 (53%) patients were classified into cohorts 1 to 4, respectively. Patients with primary lesions involving the distal esophagus were more likely to undergo intensive surveillance which involved imaging studies and endoscopic procedures (p = 0.001). Individuals affected by specific histological subtypes, such as squamous cell carcinoma and the signet cell variant, and those whose disease were managed with definitive chemoradiotherapy without surgery were also more inclined to receive intensive follow-up (p = 0.008 and p = 0.001, respectively) There were no significant differences in overall (p = 0.34) or relapse-free survival (p = 0.59) among the different surveillance strategies, even after adjusting for measured prognostic factors.

Conclusion: In this population-based analysis, outcomes of GE cancer were comparable irrespective of surveillance strategy. Intensive follow-up with routine imaging and endoscopy may not be justified given the financial implications of these costly investigations.

Citing Articles

Evaluation of post-operative surveillance strategies for esophageal and gastric cancers: a systematic review and meta-analysis.

Chidambaram S, Sounderajah V, Maynard N, Markar S Dis Esophagus. 2022; 35(12).

PMID: 35788834 PMC: 9753041. DOI: 10.1093/dote/doac034.


Prospective multicentre randomised clinical trial comparing survival rates, quality of life and nutritional status between advanced gastric cancer patients with different follow-up intensities: study protocol for the STOFOLUP trial.

Eom B, Koo D, An J, Lee H, Kim H, Hur H BMJ Open. 2021; 11(12):e056187.

PMID: 34880028 PMC: 8655561. DOI: 10.1136/bmjopen-2021-056187.


Predictive Role of Endoscopic Surveillance after Total Gastrectomy with R0 Resection for Gastric Cancer.

Lee J, Lee J, Kim J, Na H, Ahn J, Jung K J Korean Med Sci. 2021; 36(14):e88.

PMID: 33847079 PMC: 8042482. DOI: 10.3346/jkms.2021.36.e88.


Survivorship care for cancer patients in primary versus secondary care: a systematic review.

Vos J, Wieldraaijer T, van Weert H, van Asselt K J Cancer Surviv. 2020; 15(1):66-76.

PMID: 32815087 PMC: 7822798. DOI: 10.1007/s11764-020-00911-w.


Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus.

Shimizu D, Koike M, Kanda M, Sonohara F, Hattori N, Hayashi M Surg Today. 2020; 51(1):153-158.

PMID: 32638131 DOI: 10.1007/s00595-020-02072-w.


References
1.
Renehan A, Egger M, Saunders M, ODwyer S . Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002; 324(7341):813. PMC: 100789. DOI: 10.1136/bmj.324.7341.813. View

2.
Jeffery M, Hickey B, Hider P . Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007; (1):CD002200. DOI: 10.1002/14651858.CD002200.pub2. View

3.
Chen L, Song M, Lin H, Hao L, Jiang X, Li Z . Chemotherapy and resection for gastric cancer with synchronous liver metastases. World J Gastroenterol. 2013; 19(13):2097-103. PMC: 3623989. DOI: 10.3748/wjg.v19.i13.2097. View

4.
Sjoquist K, Burmeister B, Smithers B, Zalcberg J, Simes R, Barbour A . Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12(7):681-92. DOI: 10.1016/S1470-2045(11)70142-5. View

5.
Greenstein A, Litle V, Swanson S, Divino C, Packer S, Wisnivesky J . Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008; 112(6):1239-46. DOI: 10.1002/cncr.23309. View